scPharmaceuticals Earnings Reports

scPharmaceuticals reported strong growth in Q4 2024 with FUROSCIX revenue doubling year-over-year. Despite higher revenues, the company faced increased operating expenses leading to a net loss. Key milestones included FDA approval for an expanded FUROSCIX indication and continued expansion efforts in Integrated Delivery Networks.

scPharmaceuticals reported a net FUROSCIX revenue of $10.0 million for Q3 2024, a 164% increase compared to Q3 2023. The company also received approval for label expansion to include NYHA Class IV patients and announced positive data on its Autoinjector program. A transformative financing of $125 million is expected to fund operations through expected profitability. The company reported a net loss of $35.1 million, or $0.75 per share, which included one-time charges of $0.47 per share.

scPharmaceuticals reported Q2 2024 net FUROSCIX revenue of $8.1 million, a 33% increase sequentially, with approximately 9,300 FUROSCIX doses filled. The company completed financing to extend cash runway through expected profitability and advanced FUROSCIX growth initiatives, including label expansion and sNDA submissions.

scPharmaceuticals generated $6.1 million in net FUROSCIX revenue for Q1 2024, despite an estimated 10% impact from the Change Healthcare cyberattack. The company ended the quarter with $58.4 million in cash and cash equivalents.

scPharmaceuticals reported Q4 2023 net FUROSCIX® revenue of $6.1 million, representing a 61% sequential growth from Q3 2023. The company ended the year with $76 million in cash, cash equivalents, and short-term investments.

scPharmaceuticals generated $3.8 million in net FUROSCIX revenue and ended Q3 2023 with $90.2 million in cash, cash equivalents, and short-term investments. The company also reached an agreement with a large IDN for FUROSCIX access and added 12 sales territories.

scPharmaceuticals reported net FUROSCIX revenue of $1.6 million and ended the quarter with $102.9 million in cash, cash equivalents and short-term investments. The company is also planning to file for NYHA Class IV indication expansion by the end of 2023.

scPharmaceuticals announced the launch of FUROSCIX and reported $2.1 million in net FUROSCIX revenue for Q1 2023. The company ended the quarter with $116.1 million in cash, cash equivalents and short-term investments. Net loss for the quarter was $11.2 million.

scPharmaceuticals reported a net loss of $9.2 million for the fourth quarter of 2022 and ended the quarter with $118.4 million in cash, cash equivalents, restricted cash and investments. The company commenced the launch and commercial availability of FUROSCIX in February 2023.

scPharmaceuticals reported a net loss of $10.2 million for the third quarter of 2022 and ended the quarter with $45.4 million in cash, cash equivalents, restricted cash and investments. The FDA approved FUROSCIX in October 2022, and the company entered into a secured debt financing agreement for up to $100 million with Oaktree Capital.

scPharmaceuticals announced FDA acceptance of FUROSCIX® New Drug Application and Prescription Drug User-Fee Act target action date of October 8, 2022. The company ended the second quarter with $56.0 million in cash, cash equivalents, restricted cash and investments. scPharmaceuticals reported a net loss of $9.7 million for the second quarter of 2022.

scPharmaceuticals reported a net loss of $7.7 million for the first quarter of 2022. The company ended the quarter with $65.6 million in cash, cash equivalents, restricted cash and investments. The FDA has accepted for review its New Drug Application (NDA) resubmission for FUROSCIX with a target action date of October 8, 2022.

scPharmaceuticals Inc. reported a net loss of $7.3 million for the fourth quarter of 2021 and ended the quarter with $75.5 million in cash, cash equivalents, restricted cash and investments. The company is preparing for the potential commercial launch of FUROSCIX in Q4 2022, pending FDA approval.

scPharmaceuticals reported a net loss of $6.6 million for the third quarter of 2021 and ended the quarter with $85.0 million in cash, cash equivalents, restricted cash and investments. The FUROSCIX NDA resubmission is planned for Q1 2022.

scPharmaceuticals reported a net loss of $7.1 million for Q2 2021. They ended the quarter with $90.2 million in cash, cash equivalents, restricted cash and investments. The company is targeting FUROSCIX NDA resubmission in Q4.

scPharmaceuticals reported a net loss of $7.1 million for the first quarter of 2021, and ended the quarter with $96.5 million in cash, cash equivalents, restricted cash and investments. The company is focused on advancing FUROSCIX and expects to resubmit the NDA in the fall of 2021.

scPharmaceuticals reported a net loss of $7.8 million for the fourth quarter of 2020, and ended the quarter with $105.3 million in cash, cash equivalents, restricted cash and investments. The company believes its cash is sufficient to fund operations through potential FUROSCIX approval and launch into 2023.

scPharmaceuticals reported a net loss of $9.0 million for the third quarter of 2020. The company is actively engaged with the FDA in their ongoing review of the FUROSCIX NDA and enrolled the first patient in the FREEDOM-HF study.

scPharmaceuticals reported a net loss of $8.3 million for the second quarter of 2020. The company's cash, cash equivalents, restricted cash, and investments totaled over $119 million as of June 30, 2020.

scPharmaceuticals reported a net loss of $7.1 million for the first quarter of 2020. They ended the quarter with $75.5 million in cash, cash equivalents, and restricted cash. The company is adjusting its prior forecasted 2020 loss to be in the range of $36.0 to $40.0 million for the fiscal year.

scPharmaceuticals reported a net loss of $10.8 million for the fourth quarter of 2019, compared to $5.1 million for the comparable period in 2018. The company ended the quarter with $72.8 million in cash, cash equivalents and restricted cash.